Application Notes

DAICEL’s CHIRALPAK® sub-2 µm columns yield sub 30-second chiral separations of Thalidomide and Naproxen under SFC conditions.

This application note provides quantitative analysis of δ9-THC from cannabidiol oil using a pyroprobe interfaced to a GC–MS.

This note looks at the analysis of N-nitrosamines in rubber teats, soothers, and toys, with specific focus on babies and young children under UK method BS EN 71-12:2016.

Reveal more in your food. Using QSight LC–MS/MS to get a fast, selective, and sensitive multi-residue method for the determination of 136 pesticides in pepper.

Isocratic HPLC method for the analysis of mycotoxins and aflatoxins uses the DFL-10 filter fluorescence detector with a photochemical reactor to improve sensitivity.

-Why ultrafiltration is important in chromatography -Applications for ultrafiltration -Using Vivaspins® for sample clarification

Method development for simultaneous analysis of ultrashort-chain, alternative, and legacy per- and polyfluoroalkyl substances (PFAS).

Method Development for Simultaneous Analysis of Ultrashort-Chain, Alternative, and Legacy per- and polyfluoroalkyl substances (PFAS).

• Improving disk extraction for Method 625.1 • Successful disk extraction for Method 8270E • Advantages of disk extraction for Method 1664B Oil & Grease

An AI treatment based on neural algorithms can now solve non-linear and unpredictable random variations of retention times inherent in chromatography technology.

Click the title above to open LCGC Europe Supplement May 2020, Volume 33, Number s5, in an interactive PDF format.

This application approaches how to achieve better resolution by evaluating and optimizing the gradient program when using a bioZen WidePore C4 LC column.

bioZen WidePore C4 is built upon core-shell technology with bioinert hardware to offer optimal particle and pore-size morphology for high reproducibility and resolution.

To overcome peak broadening, this application adjusts the column temperature for the bioZen WidePore C4 to improve peak shape for large molecules

This application analyzes how to reduce peak widths by adjusting the flow rate for intact and reduced NIST mAb when using a bioZen WidePore C4 LC column.

In this application, temperature, gradient program, and flow rates are explored and optimized for intact mass applications for mAbs when using bioZen WidePore C4.

PharmaFluidics’ μPAC™ capLC is evaluated for different user needs ranging from 12 samples per day in comprehensive mode to 65 samples per day in throughput mode.

Accurate and rapid food safety testing is an essential part of protecting our food supply. This LCGC ebook on Streamlined Analytical Workflows for Food Safety Testing focuses on new validated workflows that streamline food safety testing and address several challenges faced by laboratories.

This short application note demonstrates the effectiveness of the Microlute™ Protein Precipitation Plate for the removal of proteins.

YMC’s latest HIC column is used to analyse the DAR of Brentuximab vedotin allowing higher flow rates and shorter run times thanks to the pressure resistant particle.

The dedicated SEC column for antibodies, YMC-SEC MAB, is used to separate the MAb monomer from its aggregates as well as from degradation products in a single run.

The less hydrophobic wide-pore column YMC-Triart Bio C4 is used for the analysis of modified oligonucleotides due to the hydrophobic character of the disulfide units.

YMC-Triart Bio C4 is used in YMC capillary column format to analyse and identify intact commercial MAbs by micro-LC- MS/MS at an elevated temperature of 75°C.

This application note shows how to achieve narrow peaks and high sensitivity by optimising the AEX separation of phosphorothioate oligonucleotides (PS) in only 5 steps.

In this application note eight intact proteins in the protein mix MSRT2 are analysed by Micro-LC–MS using an YMC-Triart Bio C4 capillary column.

This application note using YMC-Triart Bio C4 shows a robust separation at high temperatures of 3 commercially available MAbs: Ofatumumab, Palivizumab, and Panitumumab.